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Abstract: A series of novel functionalized methyl 3-(hetero)arylthieno[3,2-b]pyridine-2-carboxylates
2a–2h were synthesized by C-C Pd-catalyzed Suzuki-Miyaura cross-coupling of methyl 3-bromothie-
no[3,2-b]pyridine-2-carboxylate with (hetero)aryl pinacol boranes, trifluoro potassium boronate salts
or boronic acids. Their antitumoral potential was evaluated in two triple negative breast cancer
(TNBC) cell lines—MDA-MB-231 and MDA-MB-468, by sulforhodamine B assay. Their effects on the
non-tumorigenic MCF-12A cells were also evaluated. The results demonstrated that three compounds
caused growth inhibition in both TNBC cell lines, with little or no effect against the non-tumorigenic
cells. The most promising compound was further studied concerning possible effects on cell viability
(by trypan blue exclusion assay), cell proliferation (by bromodeoxyuridine assay) and cell cycle
profile (by flow cytometry). The results demonstrated that the GI50 concentration of compound 2e
(13 µM) caused a decreased in MDA-MB-231 cell number, which was correlated with a decreased in
the % of proliferating cells. Moreover, this compound increased G0/G1 phase and decreased S phases,
when compared to control cells (although was not statistic significant). Interestingly, compound 2e
also reduced tumor size using an in ovo CAM (chick chorioallantoic membrane) model. This work
highlights the potential antitumor effect of a novel methyl 3-arylthieno[3,2-b]pyridine-2-carboxylate
derivative.
Keywords: anticancer activity; Suzuki-Miyaura coupling; thieno[3,2-b]pyridines; triple negative
breast cancer
1. Introduction
Regardless the great number of research studies worldwide to improve our under-
standing and effort to develop new therapies, breast cancer is still the most frequent
diagnosed cancer and the main cause of cancer death in women [1]. Nowadays, due to a
recent histopathologic classification, breast cancer is divided into different subtypes de-
pending on the expression of key proteins such as human epidermal growth factor receptor
2 (HER-2) estrogen and progesterone receptors; Ki67; claudins; epidermal growth factor
receptor (EGFR) and others. Thus, the subtypes of breast cancer are designated as luminal
A, luminal B, HER2-enriched (+), basal-like and claudin-low [2]. The most aggressive,
invasive and with poor prognosis type of breast cancer is the triple negative breast cancer
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(TNBC), which is immunohistochemically characterized by the lack of estrogen receptor,
progesterone receptor and absence of HER2 amplification [1]. TNBC accounts for 15 to
20% of breast cancer cases and is a highly heterogenic and aggressive type of cancer, with
patients having better response to neoadjuvant therapy [3]. Although the knowledge about
breast cancer has considerably evolved in the last years, no advances have been made
regarding TNBC treatment, thus chemotherapy remains the standard therapeutic approach
for all stages of TNBC [4]. For that reason, the discovery of novel drugs is crucial to find
new therapeutic options for treatment of TNBC.
Over the last years, several thienopyridine derivatives have been synthesized based on
the high probability of having different biological properties, namely for cancer treatment.
In 2004, Munchhof et al. reported the synthesis of substituted 7-(indol-5-yl)aminothieno
[3,2-b]pyridines and their potential as inhibitors of the vascular endothelial growth factor
receptor 2 (VEGFR-2), which is a receptor of tyrosine kinase that triggers signalization path-
ways that cause endothelial cell proliferation and tumor vascularization (angiogenesis) [5].
Boschelli et al. reported in 2005 the synthesis of 2-heteroaryl substituted 7-[(2,4-dichloro-5-
methoxyphenyl)amino]thieno [3,2-b]pyridine-6-carbonitriles, which act by inhibiting the
non-receptor tyrosine kinase Src, a kinase implicated in cancer, osteoporosis and ischemic
diseases when is overexpressed or overactivated [6]. In 2008, Claridge et al. showed that
substituted 7-arylethers of thieno[3,2-b]pyridine phenylacetylthioureas inhibit VEGFR-2
and c-Met (receptor for hepatocyte growth factor) both implicated in angiogenesis acting
synergistically [7].
Since 2010, both research groups involved in this work have been interested in the
synthesis and antitumor evaluation of new functionalized thieno[3,2-b]pyridines, either on
the pyridine ring by C-C Suzuki-Miyaura [8], Sonogashira [9], C-N Buchwald-Hartwig and
C-O Ullmann [10] couplings, or on the thiophene by C-N coupling [11] and C-C Sonogashira
followed by intramolecular cyclization [12]. Some of the compounds synthesized in the
referred works showed GI50 values below 10 µM in different human tumor cell lines and for
the most promising compounds, some insights on the mechanism of action were assessed,
namely, the effects in the cell cycle of NCI-H460 cells by flow cytometry and in apoptosis
using Annexin(V)-PI.
Queiroz et al. later reported the synthesis and biological evaluation of novel 1-aryl-3-
[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas with hydrophobic groups m- or p-F, m-CH3,
m-CF3, and m-CF3/p-Cl (substitution pattern of Sorafenib) relative to the urea moiety
in the terminal aryl ring, as antiangiogenic compounds using several assays in Human
Umbilical Endothelial Cells (HUVEC) [13]. Compounds bearing m-F, m-CH3 and m-CF3/p-
Cl showed also antitumor potential against two different human breast cancer cell lines,
MCF-7 (Estrogen receptor positive, ER+) and MDA-MB-231 (TNBC). These compounds also
showed very low cytotoxicity in the MCF-10A cell line from non-tumorigenic mammary
epithelial cells [14].
In summary, some thieno[3,2-b]pyridine derivatives have already demonstrated their
potential as anticancer and/or antiangiogenic agents.
Herein the synthesis of novel methyl 3-(hetero)arylthieno[3,2-b]pyridine-2-carboxylates
by C-C Suzuki Miyaura cross-coupling is presented. Their antitumor potential was further
evaluated in two different TNBC cell lines. Three of the thieno[3,2-b]pyridine derivatives
presented antitumor activity against the TNBC MDA-MB-231 and MDA-MD-468 cells,
without showing relevant toxicity against a non-tumorigenic mammary epithelial cell
line (MCF-12A). Moreover, compound 2e significantly decreased the number of viable
cells and cellular proliferation of MDA-MB-231 cells, as well as, increased G0/G1 phase
and decreased S phase (although not statistically significant). Importantly, compound 2e
also decreased the size of in ovo grafts of chick chorioallantoic membrane (CAM) with
MDA-MD-231 cells. Thus, this work points to the antitumor potential of a series of novel
thienopyridine derivatives, highlighting one compound as a promising molecule against
TNBC.
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2. Results
2.1. Synthesis of Methyl 3-(hetero)arylthieno[3,2-b]pyridine-2-carboxylates 2a–2h
The precursor methyl 3-bromothieno[3,2-b]pyridine-2-carboxylate 1 was prepared
according to a known procedure, from the corresponding 3-amino compound [15] us-
ing t-BuONO and CuBr2 [12], and it was reacted with several commercial (hetero)aryl
pinacolboranes, trifluoro potassium boron salts or boronic acids under Pd-catalyzed Suzuki-
Miyaura [8,16–18] cross-coupling conditions (1.2–1.6 equiv. of the boronated compound,
2–4 mol% of Pd(dppf).CH2Cl2 (1:1), 6 equiv. of K2CO3 in DME:H2O (3:1) at 100 ◦C for
3–4.5 h) to give the methyl 3-(hetero)arylthieno[3,2-b]pyridine-2-carboxylates 2a–2h in
moderate to high yields (35–84%) after column chromatography (Table 1). Compounds
2a–2h were prepared with no substituents, with electron donating groups—EDGs—(OMe,
Me) and electron withdrawing groups—EWGs—(Cl, CN, CF3) in the para-position of the
phenyl ring relative to the C-C bond formed or with an electron-deficient ring (pyridine) or
an electron-rich one (furan).
Table 1. Synthesis of methyl 3-(hetero)arylthieno[3,2-b]pyridine-2-carboxylates 2a–2h products.
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Having compounds 2a–2h in hands their potential as antitumor compounds was
evaluated.
2.2. Cell Growth Inhibitory Effect of the Synthesized Compounds on Two Different TNBC Cell
Lines
The antitumor potential of the synthesized compounds 2a–2h was evaluated in vitro
using the sulforhodamine B (SRB) assay [19,20], which allows to determine the GI50 concen-
tration of each compound, i.e., the drug concentration that inhibits 50% of the cell growth.
Thus, the compounds were tested in two different triple negative breast cancer (TNBC) cells,
MDA-MB-231 and MDA-MB-468. Unfortunately, it was not possible to determine the GI50
values for some of the compounds synthesized, since these compounds formed crystals
in the culture medium at higher concentrations. Therefore, in these cases, the GI50 values
were considered higher than the maximum concentration tested without crystal formation.
Results presented in Table 2 demonstrated that three of the synthesized compounds (2e, 2f,
2h) tested significantly inhibited the growth of both TNBC cell lines with a GI50 relatively
low. Indeed, compound 2h presented the lowest GI50 value in the MDA-MB-468 TNBC cell
line. Even though it was not possible to establish structure-activity relationships (SARs), the
furan derivative 2h, with an electron-rich ring, seems more selective for the MDA-MB-468
cell line. Moreover, the same was observed for compound 2f with an EWG (p-CN). Taken
together compounds 2e, 2f and 2h, showed promising anticancer activity against TNBC
cell lines.
Table 2. GI50 concentrations of compounds 2a–2h in two different triple negative breast cancer cells,
determined with SRB assay.
GI50 * Concentrations (µM) for Each Cancer Cell Line





2e 12.56 ± 1.88 >14
2f 28.67 ± 1.34 8.73 ± 1.73
2g >75 >75
2h >75 4.67 ± 0.68
Doxorubicin 0.068 ± 0.006 0.081 ± 0.009
* GI50 values correspond to the mean ± S.E.M. of at least three independent experiments, all performed in
duplicated. When not possible to determine the GI50 due to the formation of crystals, the highest concentration
tested in which crystals were not observed is presented (GI50 higher than that concentration).
2.3. Evaluation of the Cytotoxicity of the Most Promising Compounds against a Non-Tumorigenic
Cell Line
The most promising compounds 2e, 2f and 2h, were then evaluated regarding their
toxicity against the non-tumorigenic mammary epithelial MCF-12A cell line. For that, the
SRB assay was performed using the GI50 concentrations of each of the three compounds
obtained in the corresponding TNBC cell lines. The results (Table 3) demonstrated that
compounds 2e, 2f and 2h, at the GI50 concentrations previously obtained in the most
sensitive TNBC cancer cell line (Table 2), caused a small or no effect in the growth of
the non-tumorigenic MCF-12A cells. These results suggest that the three compounds
are selective for cancer cells, not affecting the non-tumorigenic cell line, at least at the
concentrations tested. It should be noted that the duration of the SRB assay carried out
in the non-tumorigenic cells is longer than the SRB assay carried out in cancer cells, since
the non-tumorigenic cells have a slower cell growth rate. This longer duration of the assay
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allows evaluation of possible delayed toxic effects of the compounds in the non-tumorigenic
cells.
Table 3. Evaluation of the cytotoxicity of the three most promising compounds in the non-tumorigenic cell line MCF-12A,
using the SRB assay.
Compounds Concentrations Tested (µM)(GI50 Concentration in the Tumor Cell Lines)
% Cell Growth in MCF-12A Cell Line
(Relative to the Control) *
2e 12.56 88.62 ± 4.04
2f 8.73 117.73 ± 3.22
2h 4.67 82.13 ± 4.78
* Values correspond to the mean ± S.E.M. of at least three independent experiments, all performed in duplicate. The % of growth of the
cell line MCF-12A was determined using the GI50 concentrations of each compound, in the most sensitive tumor cell lines previously
determined (Table 2).
2.4. Effect of Compound 2e on Number of Viable Cells and on the Proliferation of TNBC
MDA-MB-231 Cells
Compound 2e has the particularity of having part of its hydrophobic tail (the phenyl
ring bearing a Cl atom) similar to Sorafenib [21], which is an antiangiogenic drug known
as an active multikinase inhibitor, currently approved for the treatment of different types
of cancers [22]. However, Sorafenib has not been included in the clinical practice for breast
cancer treatment given its high toxicity [23,24].
Therefore, we decided to conduct some preliminary activity studies on compound
2e. Its effect on TNBC viable cell number and cell proliferation was assessed after 48 h
treatment, using the trypan blue exclusion assay and the bromodeoxyuridine (BrdU)
incorporation assay, respectively. For that, the MDA-MB-231 cell line was treated with
the GI50 concentration of compound 2e, which corresponds to 13 µM, with the vehicle
DMSO (control; at the same concentration used for the compound), and doxorubicin,
used as positive control. The obtained results demonstrated that as expected, doxorubicin
significantly reduced MDA-MB-231 viable cell number. In addition, the GI50 concentration
of compound 2e significantly reduced MDA-MB-231 viable cell number in comparison
with the control treatment (Figure 1).
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Figure 1. Effect of compound 2e on MDA-MB-231 viable cell number, d termined by trypan blue
exclusion assay. ll t for 48 h with medium (Blank), control (DMSO; vehicle), compound
2e (at 13 µM) and Doxorubicin (positive control; 50 nM). Results represent the mean ± S.E.M. of at
least three independent experiments. ** p ≤ 0.01 and *** p ≤ 0.001 of Control vs. Treatments.
Moreover, as expected, doxorubicin significantly reduced MDA-MB-231 cellular prolif-
eration. Furthermore, th GI50 concentratio of compound 2e also significantly dec eased
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the % of proliferating MDA-MB-231 cells, when compared to the control (Figure 2). These
results suggested that compound 2e interferes with the TNBC viable cell number and
proliferation.
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2.5. Effect of o pound 2e on ell ycle Profile in T B - B-231 ells
onsidering the previous results, we further analyzed the possible effect of compound
2e on TNBC MDA-MB-231 cell cycle profile, assessed after 48 h treatment, using the flow
cytometry analysis with propidium iodide (PI). For that, the MDA-MB-231 cell line was
treated with 13 µM of compound 2e (GI50 concentration), the vehicle DMSO (control) and
doxorubicin. As predictable, doxorubicin (used as positive control) significantly increased
the G0/G1 phase and decreased S and G2/M phases in the MDA-MB-231 cells. The
results demonstrated that the GI50 concentration of compound 2e, although not statistically
significant, increased G0/G1 phase and decreased S phase, when compared to control cells
(Figure 3). These results suggested that compound 2e interferes with the cell cycle profile
of TNBC MDA-MB-231 cells.
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2.6. Antitumor Effect of Compound 2e in Ovo Grafted with MDA-MB-231 Cells Using the Chick
Chorioallantoic Membrane (CAM) Assay
The above results indicate that compound 2e is the most promising compound against
the MDA-MD-231 cell line. In addition, this compound decreased the number of viable
and proliferating tumor cells. Since compound 2e has a structural similarity with the
antiangiogenic drug Sorafenib, the study of the antiangiogenic and antitumor potential of
this compound was attempted using the chick embryo chorioallantoic membrane (CAM)
assay [25]. Thus, CAM assay was performed by grafting TNBC MDA-MB-231 cells in ovo,
in order to create tumors in the eggs, which was followed by testing the effect of the GI50
concentration (13 µM) of compound 2e on tumor formation.
Results showed that (Figure 4A) treatment of grafted eggs for 48 h with the GI50
concentration of compound 2e efficiently decreased tumor formation (tumor size), when
compared with the control group (vehicle). Unfortunately, the antiangiogenic potential
was not possible to analyze due to the high vascularization induced by breast cancer cells,
which led to some degree of inflammation. The reduction in tumor size was well visible
(Figure 4B). In addition, using hematoxylin and eosin (H&E) staining, viability of tumors
at both conditions was confirmed (Figure 4B). Remarkably, the CAM assay confirmed a
promising anti-tumorigenic effect of compound 2e, although no information regarding the
antiangiogenic potential was possible to obtain.
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3. Discussion
From the eight methyl 3-(hetero)arylthieno[3,2-b]pyridine-2-carboxylates 2a-2h syn-
thesized (Table 1), the compounds obtained with the best yields were 2a (Ph), 2b (p-Me),
2c (p-OMe) without substitution or with EDGs, and 2e (p-Cl). Although for phenyl rings
bearing EWGs (p-CF3 and p-CN) the yields were only moderate, for compound 2e the yield
was excellent (82%) may be due to the positive mesomeric effect of the chlorine. Despite
the different electron character of the heterocyclic rings, pyridine and furan, the resulting
compounds 2g and 2h were isolated in good yields.
The evaluation of the effect of this series of compounds on cell growth (by the SRB
assay) allowed to find the three most promising compounds, namely compounds 2e, 2f
and 2h, which under the concentrations tested showed antitumor effect in vitro against
the TNBC cell lines. Importantly, the three compounds had little or no effect against the
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non-tumorigenic cancer cell line MCF-12A, at the concentrations tested (which inhibited
the growth of the cancer cells by 50%).
Since compound 2e has the particularity of having part of its hydrophobic tail (the
phenyl ring coupled to a p-Cl atom) similar to Sorafenib, an approved anticancer agent for
other cancer types [21], it was decided to conduct preliminary studies on the antitumor
activity of this novel compound. The results demonstrated that compound 2e decreased
viable cell number and cell proliferation in the TNBC MDA-MB-231 cells. Interestingly,
compound 2e did not cause alterations in the levels of two important apoptotic markers,
PARP or caspase-3, therefore suggesting that apoptosis is not involved in the mechanism of
action of this compound (data not shown). Remarkable, this work showed that compound
2e reduced tumor size of grafted MDA-MB-231 cells in ovo CAM model. The CAM assay
allows to study the effect of compounds on the angiogenesis process, as well as to evaluate
the effect on tumor growth (tumorigenic response), being suitable as an in vivo model for
the screening of potential novel drugs, as an alternative to mouse models [26].
Interestingly, studies conducted in TNBC cells demonstrated that Sorafenib is able
to inhibit cell proliferation and tumor growth [27–29]. Similar effects were observed in
the present study, with MDA-MB-231 cells treated with compound 2e, both in vitro and in
ovo. It is possible that the hydrophobic tail might be partly responsible for the anticancer
activity of these molecules, but this hypothesis requires evaluation. Further studies should
be conducted to better understand the mechanism of action of compound 2e.
4. Materials and Methods
4.1. Synthesis
Melting points (◦C) were determined in a SMP3 Stuart apparatus. 1H, 13C and 19F
NMR spectra were recorded on a Bruker Advance III (Bruker, Bremen, Germany) at
400, 100.6 and 376.48 MHz respectively (see Suppl. Materials), using the signals of the
non-deuterated solvents of CHCl3 (7.27 ppm) of the CDCl3 or of DMSO (2.49 ppm) of
the DMSO-d6, as internal reference relatively to TMS (0 ppm). DEPT (θ = 135◦) and bi-
dimensional homo 1H–1H (COSY) and heteronuclear correlations 1H-13C (HMQC and
HMBC) were used to attribute some signals (see Supplementary Materials). Elemental
analysis was performed on a LECO CHNS 932 elemental analyzer (LECO Corporation,
Michigan, USA). The low-resolution MS spectra were obtained by ESI [M + H]+ using
a Thermo-Finnigan LXQ (Thermo Fisher Scientific, Waltham, MA, USA) at the CQUM.
HRMS were obtained at the external service of mass spectrometry of the University of
Vigo using EI (M+). Reactions were followed by thin layer chromatography (TLC). Col-
umn chromatography was performed on Macherey-Nagel silica gel 0.060–0.200 mm, 60 A,
and dry flash chromatography on silica gel 0.035–0.070 mm, 60 A, to purify the com-
pounds. Petroleum ether refers to the boiling range 40–60 ◦C. Ether refers to dietylether.
DME refers to 1,2-dimethoxyethane. The catalyst PdCl2(dppf).CH2Cl2 (1:1) refers to 1,10-
bis(diphenylphosphino)ferrocenedichloropalladium (II), complex with dichloromethane
(1:1) and was purchased from Aldrich (Sigma-Aldrich, St. Louis, MO, USA).
4.1.1. General Procedure for the Suzuki-Miyaura Cross-coupling Products 2a–h
In a round flask, DME (3 mL) and water (1 mL), compound 1, (het)aryl boronic acids,
pinacol esters, or potassium trifluoroborates (1.2–1.6 equiv.), PdCl2 (dppf).CH2Cl2 (1:1)
(2 mol% unless stated), K2CO3 (6 equiv.) were added and the mixture was heated with
stirring at 100 ◦C for 3–4.5 h. The reactions were monitored by TLC. After cooling, water
was added (10 mL) and extraction with ethyl acetate (3 × 10 mL) was performed. The
organic phases were collected, dried (MgSO4), filtered and the solvent removal under
reduced pressure gave a solid that was submitted to column chromatography or to dry
flash using solvent gradient from neat petroleum ether to mixture of ether/petroleum ether,
increasing 10% of ether each time, to give compounds 2a–2h.
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Methyl 3-phenylthieno[3,2-b]pyridine-2-carboxylate (2a)
From compound 1 (0.100 g, 0.370 mmol) and phenylboronic acid pinacol ester (0.0900 g,
0.440 mmol) following the general procedure for 3 h; purification by column chromatogra-
phy using 50% ether/petroleum ether, gave compound 2a as a white solid (0.0730 g, 74%),
m.p. 152–154 ◦C. 1H-NMR (DMSO-d6, 400MHz) δ = 3.75 (3H, s, OMe), 7.43–7.48 (5H, m,
Ar-H), 7.56 (1H, dd, J = 8.0 and 4.4 Hz, 6-H), 8.61 (1H, dd, J = 8.0 and 1.6 Hz, 7-H), 8.74
(1H, dd, J = 4.4 and 1.6 Hz, 5-H) ppm. 13C-NMR (DMSO-d6, 100.6 MHz) δ = 52.6 (OMe),
122.0 (6-CH), 127.4 (2 × CH), 128.0 (CH), 130.5 (2 × CH), 131.0 (C), 132.0 (7-CH), 133.1 (C),
134.2(C), 142.6 (C), 148.6 (5-CH), 153.3 (C), 162.1 (C=O) ppm. MS (ESI) m/z (%): 270.03
[M + H]+ (100%). Elemental Anal. calcd for C15H11NO2S: C 66.89%, H 4.12%, N 5.20%,
S 11.91%. Found: C 67.08%, H 4.09%, N 5.46%, S 12.16%.
Methyl 3-(p-tolyl)thieno[3,2-b]pyridine-2-carboxylate (2b)
From compound 1 (0.150 g, 0.554 mmol) and potassium p-tolyltrifluoroborate (0.132 g,
0.664 mmol) and heating for 4.5 h, after purification by column chromatography using 40%
ether/petroleum ether, compound 2b was obtained as a white solid (0.132 g, 84%), m.p.
153–154 ◦C. 1H-NMR (CDCl3, 400 MHz) δ = 2.44 (3H, s, Me), 3.85 (3H, s, OMe), 7.33 (2H,
d, J = 8.0 Hz, 3′ and 5′-H), 7.39 (1H, dd, J = 8.4 and 4.8 Hz, 6-H), 7.42 (2H, d, J = 8.0 Hz,
2′ and 6′-H), 8.24 (1H, dd, J = 8.4 and 1.6 Hz, 7-H), 8.80 (1H, dd, J = 4.8 and 1.6 Hz, 5-H)
ppm. 13C-NMR (CDCl3, 100.6 MHz) δ = 21.5 (Me), 52.4 (OMe), 121.1 (6-CH), 128.7 (3′ and
5′-CH), 130.1 (2′ and 6′-CH), 130.12 (C), 130.7 (7-CH), 131.2 (C), 134.9 (C), 138.2 (C), 144.0
(C), 148.5 (5-CH), 154.6 (C), 162.7 (C=O) ppm. MS (ESI) m/z (%): 284.07 [M + H]+ (83%).
Elemental Anal. calcd for C16H13NO2S: C 67.82%, H 4.62%, N 4.94%, S 11.32%. Found: C
68.15, H 4.35, N 5.20, S 11.69%.
Methyl 3-(4-methoxyphenyl)thieno[3,2-b]pyridine-2-carboxylate (2c)
From compound 1 (0.100 g, 0.370 mmol) and potassium 4-methoxyphenyltrifluoroborate
(0.094 g, 0.440 mmol), reacting for 4 h, after purification by column chromatography using
25% ether/petroleum ether, compound 2c was obtained as a white solid (0.0770 g, 70%),
m.p. 190–191 ◦C. 1H-NMR (CDCl3, 400MHz) δ = 3.85 (3H, s, OMe), 3.89 (3H, s, OMe), 7.05
(2H, d, J = 8.8 Hz, 3′ and 5′-H), 7.39 (1H, dd, J = 8.0 and 4.4 Hz, 6-H), 7.50 (2H, d, J = 8.8 Hz,
2′ and 6′-H), 8.23 (1H, dd, J = 8.0 and 1.6 Hz, 7-H), 8.80 (1H, dd, J = 4.4 and 1.6 Hz, 5-H)
ppm. 13C-NMR (CDCl3, 100.6 MHz) δ = 52.5 (OMe), 55.2 (OMe), 113.4 (3′ and 5′-CH), 121.1
(6-CH), 125.2 (C), 130.7 (7-CH), 130.9 (C), 131.6 (2′ and 6′-CH), 134.9 (C), 143.6 (C), 148.5
(5-CH), 154.2 (C), 159.7 (4′-C), 162.9 (C=O) ppm. MS (ESI) m/z (%): 300.06 [M + H]+ (100%).
Elemental Anal. calcd for C16H13NO3S: C 64.20%, H 4.38%, N 4.68%, S 10.71%. Found: C
64.20%, H 4.45%, N 4.84%, S 10.33%.
Methyl 3-[4-(trifluoromethyl)phenyl]thieno[3,2-b]pyridine-2-carboxylate (2d)
From compound 1 (0.100 g, 0.370 mmol) and potassium 4-(trifluoromethyl)phenyltri-
fluoroborate (0.106 g, 0.440 mmol), reacting for 4 h, after purification by column chromatog-
raphy using 40% ether/petroleum ether, compound 2d was obtained as a white solid. This
was recrystallized from ether to give a colorless crystals (0.0350 g, 40%), m.p. 170–171 ◦C.
1H-NMR (CDCl3, 400MHz) δ = 3.85 (3H, s, OMe), 7.43 (1H, broad d, 6-H), 7.66 (2H, d,
J = 8.0 Hz, 2′ and 6′-H), 7.78 (2H, d, J = 8.0 Hz, 3′ and 5′-H), 8.28 (1H, broad d, J = 8.0 Hz,
7-H), 8.80 (1H, broad s, 5-H) ppm. 13C-NMR (CDCl3, 100.6 MHz) δ = 52.7 (OMe), 120.6
(6-CH), 124.8 (q, J = 271.62 Hz, CF3), 124.9 (q, J = 3.6 Hz, 3′ and 5′-CH), 130.3 (q, J = 32.4 Hz,
CCF3), 130.8 (2′ and 6′-CH), 131.0 (7-CH), 132.3 (C), 135.0 (C), 137.0 (C), 142.1 (C), 148.8
(5-CH), 153.3 (C), 162.4 (C=O) ppm. 19F-NMR (CDCl3, 376.48 MHz): δ =−62.63 (s, F3) ppm.
MS (ESI) m/z (%): 338.05 [M + H]+ (100%). Elemental Anal. calcd for C16H10F3NO2S: C
56.97%, H 2.99%, N 4.15%, S 9.51%. Found: C 56.62%, H 2.65%, N 4.35%, S 9.81 %.
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Methyl 3-(4-chlorophenyl)thieno[3,2-b]pyridine-2-carboxylate (2e)
From compound 1 (0.120 g, 0.443 mmol) and potassium (4-chlorophenyl)trifluoroborate
(0.116 g, 0.532 mmol) reacting for 3 h, purification by column chromatography using 50%
ether/petroleum ether, compound 2e was obtined as a white solid (0.102 g, 82%), m.p.
195–196 ◦C. 1H-NMR (CDCl3, 400MHz) δ = 3.85 (3H, s, OMe), 7.43 (1H, dd, J = 8.4 and
4.4 Hz, 6-H), 7.49 (4H, coalesced doublets, Ar-H), 8.27 (1H, broad d, J = 8.4 Hz, 7-H), 8.81
(1H, broad s, 5-H) ppm. 13C-NMR (CDCl3, 100.6 MHz) δ = 52.6 (OMe), 121.3 (6-CH), 128.3
(2× CH), 131.3 (7-CH), 131.7 (2× CH), 132.2 (C), 134.7 (C), 135.1 (C), 142.1 (C), 148.4 (5-CH),
153.4 (C), 157.3 (C), 162.5 (C=O) ppm. HRMS (EI) Calcd. for C15H1035ClNO2S [M + 35Cl]
303.0121; found: 303.0104. Calcd. for C15H1037ClNO2S [M+37Cl] 305.0091; found: 305.0099.
Methyl 3-(4-cyanophenyl)thieno[3,2-b]pyridine-2-carboxylate (2f)
From compound 1 (0.100 g, 0.370 mmol) and potassium (4-cyanophenyl)trifluoroborate
(0.121 g, 0.592 mmol) reacting for 3 h, gave a solid which was submitted to dry flash till
90% ether/petroleum ether to give compound 2f as a white solid (0.038 g, 35%), m.p.
198–200 ◦C. 1H-NMR (CDCl3, 400MHz) δ = 3.86 (3H, s, OMe), 7.44 (1H, dd, J = 8.0 and
4.4 Hz, 6-H), 7.65 (2H, d, J = 8.4 Hz, 2′ and 6′-H), 7.80 (2H, d, J = 8.4 Hz, 3′ and 5′-H), 8.27
(1H, broad dd, 7-H), 8.78 (1H, broad d, 5-H) ppm. 13C-NMR (CDCl3, 100.6 MHz) δ = 52.7
(OMe), 112.2 (C), 118.9 (C), 121.5 (6-CH), 131.0 (7-CH), 131.3 (2 × CH), 131.6 (2 × CH),
132.6 (C), 135.0 (C), 138.1 (C), 141.4 (C), 148.8 (5-CH), 153.4 (C), 162.2 (C=O) ppm. HRMS
(EI) M+ Calcd. for C16H10N2O2S: 294.0463; found: 294.0474.
Methyl 3-(pyridin-4-yl)thieno[3,2-b]pyridine-2-carboxylate (2g)
From compound 1 (0.120 g, 0.443 mol) and 4-pyridine boronic acid (0.0790 g,
0.709 mmol), of PdCl2(dppf).CH2Cl2 4 mol% and heating for 4 h, a solid was obtained and
submitted to dry flash chromatography till 80% ether/petroleum ether to give compound
2g as a white solid (0.0400 g, 66%), m.p. 192–193 ◦C. 1H-NMR (CDCl3, 400MHz) δ = 3.90
(3H, s, OMe), 7.50 (1H, dd, J = 8.4 and 4.4 Hz, 6-H), 7.90 (2H, broad d, 3′ and 5′-H), 8.32
(1H, dd, J = 8.4 and 1.2 Hz, 7-H), 8.79–8.82 (3H, m, 5-H and 2′ and 6′-H) ppm. 13C-NMR
(CDCl3, 100.6 MHz) δ = 53.1 (OMe), 122.0 (6-CH), 127.8 (3′ and 5′-CH), 131.1 (7-CH), 134.4
(C), 135.1 (C), 137.7 (C), 139.3 (C), 143.0 (2′ and 6′-CH), 149.3 (5-CH), 152.6 (C), 161.7 (C=O)
ppm. MS (ESI) m/z (%): 271.04 [M + H]+ (100%). Elemental Anal. calcd for C14H10N2O2S:
C 62.21%, H 3.73%, N 10.36%, S 11.86%. Found: C 61.90%, H 3.69%, N 10.06%, S 11.79%.
Methyl 3-(furan-3-yl)thieno[3,2-b]pyridine-2-carboxylate (2h)
From compound 1 (0.120 g, 0.443 mmol), potassium 3-furanylboronic acid (0.0706 g,
0.709 mmol), PdCl2(dppf).CH2Cl2 4%mol and heating for 4.5 h, a solid was obtained and
submitted to dry flash chromatography till 30 % ether/petroleum ether to give compound
2h as a white solid (0.0700 g, 52%), m.p. 130–132 ◦C. 1H-NMR (CDCl3, 400MHz) δ = 3.94
(3H, s, OMe), 7.02–7.03 (1H, m, HetAr-H), 7.40 (1H, dd, J = 8.4 and 4.4 Hz, 6-H), 7.56–7.57
(1H, m, HetAr-H), 8.21 (1H, dd, J = 8.4 and 1.6 Hz, 7-H), 8.25–8.26 (1H, m, HetAr-H), 8.81
(1H, dd, J = 4.4 and 1.6 Hz, 5-H) ppm. 13C-NMR (CDCl3, 100.6 MHz) δ = 52.6 (OMe), 112.3
(CH), 116.7 (C), 121.2 (6-CH), 130.0 (C), 130.6 (7-CH), 134.5 (C), 134.6 (C), 141.8 (CH), 144.3
(CH), 148.1 (5-CH), 153.7 (C), 162.8 (C=O) ppm. MS (ESI) m/z (%): 260.04 [M + H]+ (100%).
Elemental Anal. calcd for C13H9NO3S: C 60.22%, H, 3.50%, N 5.40%, S 12.37%. Found: C
60.27%, H 3.33%, N 5.69%, S 12.48%.
4.2. In Vitro Antitumor Evaluation
4.2.1. Reagents
Fetal bovine serum (FBS) and phosphate buffered saline (PBS) were purchased from
Biowest and Gibco, respectively. Acetic acid, dimethyl sulfoxide (DMSO), ethylene di-
amine tetraacetic acid (EDTA), sulforhodamine B (SRB), trypan blue reagent, doxorubicin,
trichloroacetic acid (TCA), Tris base and bromodeoxyuridine (BrdU) were purchased from
Sigma-Aldrich. Stock solutions of the synthesized compounds were prepared with the
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solvent DMSO as vehicle, at stock concentration of 60 mM and kept at −20 ◦C. The other
working stock solutions of 40 mM, 20 mM and 5 mM were also prepared in DMSO and
kept at −20 ◦C.
4.2.2. Solutions of the Compounds
Appropriate dilutions of compounds 2a–2h were freshly prepared from the previous
stock solutions in DMSO for the cell-based assays. The effect of the vehicle solvent (DMSO)
on the growth of the cell lines was evaluated by exposing untreated control cells to the
maximum concentration of DMSO used in each compound for each assay.
4.2.3. Cell Cultures
Two human triple negative breast cancer (TNBC) cell lines were used in this work:
MDA-MD-231 and MDA-MB-468. Both TNBC cell lines were cultured in RPMI 1640
medium (Roswell Park Memorial Institute) with 25 mM of glutamine and 4-(2-Hydroxyeth-
yl)piperazine-1-ethanesulfonic acid (HEPES) buffer (from Biowest). These media were
supplemented with 5% FBS for the cell growth inhibition assay (SRB) or with 10% FBS
for the remaining experiments. The non-tumorigenic cell line MCF-12A was cultured in
RPMI 1640 medium supplemented with hEGF (human epidermal growth factor; 20 ng/µL),
hydrocortisone (500 ng/µL), 5% FBS and 1% Penicillin-Streptomycin (Gibco), as previously
described [30]. All the cell lines were maintained as adherent cell cultures and kept at 37 ◦C
in a humidified incubator containing 5% of CO2. Regularly, all cells were observed using
an inverted light microscope (Leica DMi1). All the experiments were carried out with cells
at the exponential phase of growth and with more than 90% viability.
4.2.4. Trypan Blue Exclusion Assay
The cell number and viability were assessed by counting the cells with a hemocytome-
ter (Neubauer Chamber) using the trypan blue reagent, which distinguishes alive (bright)
from dead cells or non-viable cells (blue ones).
4.2.5. Cell Growth Inhibition Assay (SRB Assay)
The potential cytotoxicity of the compounds was tested using an assay based on a
protein-binding dye, the sulforhodamine B (SRB), according to the protocol [31]. Briefly,
cells were seeded at an appropriate concentration previously optimized (5.0 × 104 cells per
mL for MDA-MD-231 and MDA-MB468 cells) by adding 100 µL of cells per well and then
incubated at 37 ◦C for 24 h. All experiments were performed in two 96 well-plates, a T0 plate
to be analyzed at 0 h (time of treatment with the compounds) and a T48 plate to be analyzed
48 h later. Then, cells were treated with five serial dilutions of each compound (ranging
from 150 µM to 9.4 µM) by adding 100 µL of compound per well, and incubated at 37 ◦C for
further 48 h. The effect of the vehicle (DMSO) on cell growth was also evaluated (control)
by exposing untreated cells to the maximum concentration of DMSO (always lower than
0.25%). The maximum concentration tested for each compound was 150 mM. However,
for some compounds, precipitation was detected within the tested range of concentrations.
In those cases, the GI50 concentration was not possible to determine and was indicated as
“higher than” the highest concentration tested without causing precipitation. Doxorubicin
(ranging from 100 nM to 6.25 nM) was used as positive control. Following 48 h incubation
of cells with the compounds in the T48 plate (or 0 h in the T0 plate), cells were fixed by
adding 10% (w/v) of cold TCA (w/v, final concentration) during 1 h at 4
◦
C. Subsequently,
after washing with water, air-dried cells were stained with 0.4% of SRB (in acetic acid,
w/v) for 30 min in the dark at room temperature (RT). At the end, cells were washed with
1% (v/v) of acetic acid and the bound dye was solubilized with 10 mM Tris base solution.
The absorbance was measured at 510 nm in a microplate reader (BioTek’s SynergyTM Mx)
using the Gen5 software (BioTek) [19,20]. The GI50 concentrations for each compound
(concentrations that inhibited cell growth by 50%) were assessed from the dose-response
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curves, determined in each cell line and presented as mean ± standard error (S.E.M) from
at least three independent experiments.
Compounds 2e, 2f, 2h were also tested against the non-malignant MCF-12A human
breast epithelial cells. For that, cells (seed at 5.0× 104 cells per mL) were incubated with the
GI50 concentrations of each of the three compounds obtained in the corresponding tumor
cell lines for 48 h, followed by removal of the compound, addition of new medium to the
cells and then 5 more days in culture. At the end of the 7 days in total, the sulforhodamine
B (SRB) assay was performed, as previously described [30].
4.2.6. Cell Proliferation Analysis (BrdU Assay)
Cell proliferation was assessed using the bromodeoxyuridine (BrdU) incorporation
assay, according to the previously described protocol [19]. The MDA-MB-231 cells were
plated at 7 × 104 cells per mL in 6-well plates. After 24 h, cells were treated with the GI50
(13 µM) of compound 2e, medium (blank), the vehicle corresponding to DMSO (control; in a
concentration equivalent to the one used in the treatment) or 50 nM of doxorubicin (positive
control), for 48 h. After that, cells were incubated with 10 µM BrdU (Sigma-Aldrich) for 4 h.
Cells were washed and fixed with 4% paraformaldehyde, PFA (Panreac) in PBS. After the
preparation of cytospins, cells were treated with 2 M HCl for 20 min (DNA denaturation),
followed by blocking with a PBS 0.5% Tween and 0.05% Bovine Serum Albumin solution.
Cells were then incubated with a mouse anti-BrdU antibody (1:10; Dako), followed by the
incubation with anti-mouse-Ig-FITC (1:100; Dako). After that, slides were prepared with
Vectashield mounting medium containing 4′,6-diamidino-2-phenylindole, DAPI (Vector
Laboratories Inc, Burlingame, CA, USA). The detection of BrdU incorporation (green nuclei)
was possible using a Zeiss Axio Imager Z1 (Carl Zeiss, Jena, Germany) microscope and the
Axiovision 4.9 (Carl Zeiss, Jena, Germany) software. A semi-quantitative evaluation was
performed by counting a minimum of 500 cells per slide using the ImageJ 2.1.0 software.
The results were from three independent experiments, and are presented as mean ± S.E.M.
4.2.7. Cell Cycle Analysis
For cell cycle distribution analysis, MDA-MB-231 cells were plated at 7 × 104 cells
per mL in 6-well plates for 24 h. Cells were then treated with the GI50 (13 µM) of the
compound 2e, medium (blank), the vehicle DMSO (control) and 50 nM of doxorubicin
(positive control). Following 48 h incubation, cells were collected, centrifuged (1200 rpm
for 5 min) and then fixed with ice-cold 70% ethanol and stored at 4 ◦C for at least 12 h.
Cells were then centrifuged at 1200 rpm for 5 min, at 4 ◦C, and the pellets resuspended in a
solution of PBS containing 5 µg/mL propidium iodide (PI) and 0.1 mg/mL RNase A, and
incubated for at least 30 min in the dark on ice, prior to each analysis on the flow cytometer.
Cellular DNA content for cell cycle distribution was analyzed by flow cytometry using
the BD Accuri™ C6 Flow Cytometer (BD Biosciences). The exclusion of cell debris and
aggregates was performed for each analysis, and at least 20,000 events per sample were
plotted for all the acquisitions. Data was analyzed using the FlowJo software (version 7.6.5,
Tree Star, Inc., Ashland, OR, USA) [19]. The results were from at least three independent
experiments, and are presented as mean ± S.E.M.
4.3. In Ovo Evaluation
In Vivo Chick Egg Chorioallantoic Membrane (CAM) Model
The chick embryo chorioallantoic membrane (CAM) model was used to evaluate
the tumorigenic response of compound 2e. Fertilized chick (Gallus gallus) eggs were
obtained from commercial sources, and incubated horizontally at 37.8 ◦C, in a humidified
atmosphere and referred to the embryonic development day (EDD). Ethical approval is not
required for experiments using embryonic chicken according to the European Directive
2010/63/EU and the Portuguese law on animal welfare does not restrict the use of chicken
eggs for experimental purposes. Briefly, on EDD3, a square window was opened in the
shell after removal of 1.5–2 mL of albumin to allow detachment of the developing CAM.
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The window was sealed with a transparent adhesive tape and the eggs returned to the
incubator. The MDA-MB-231 cells were resuspended in matrigel (1:1) and grafted on
top of the same EDD9 growing CAM, into two independent 3-mm nylon rings, under
sterile conditions (7.5 × 105 cells per ring). The eggs were resealed and returned to the
incubator for an additional 24 h. At EDD10, tumor xenografts were treated with either
vehicle (DMSO) or with compound 2e pairwise. Eggs were resealed and returned to the
incubator for additional 3 days. On EDD14, embryos were euthanized by adding 2 mL of
fixative in the top of the CAM, rings were removed, the CAM was excised from embryos
and photographed ex-ovo under a stereoscope, using a 20× magnification (Olympus,
SZX16 coupled with a DP71 camera). The area of CAM tumors was determined using
the Cell A (Olympus) software. The experiment was performed in a blind fashion way,
since the identity of the treatment (vehicle or compound 2e) was not known by the person
performing the analysis. The area of CAM tumors was determined using the Olympus cell
Sens Standard 1.14 program. Excised CAMs were fixed in 10% neutral-buffered formalin,
paraffin-embedded for slide sections and stained with hematoxylin–eosin for histological
examination.
4.4. Statistical Analysis
The statistical analysis was performed using GraphPad Prism Software v5 (GraphPad-
trial version, San Diego, CA, USA). For SRB assay, the GI50 concentrations were assessed
from the dose-response curves and determined for each compound, in each cell line.
The GI50 values presented are the mean ± standard error (S.E.M.) from at least three
independent experiments. For BrdU and cell cycle analysis, the % of proliferating cells or
cells in each cell cycle phase was determined, and the results presented are the mean ±
S.E.M. of at least three independent experiments. In the CAM assay, the data (n = 19) were
analyzed for Gaussian distribution and passed the D’Agostino and Pearson normality tests.
To test the hypothesis that compound 2e treated tumors are different from the vehicle, a
paired t-test was used. Statistical significance was achieved when p value < 0.05.
5. Conclusions
Eight novel methyl 3-(hetero)arylthieno[3,2-b]pyridine-2-carboxylates 2a–2h were
prepared in moderate to high yields by C-C Pd-catalyzed Suzuki-Miyaura cross-coupling of
methyl 3-bromothieno[3,2-b]pyridine-2-carboxylate with different boronated compounds.
These were tested against TNBC cell lines and the potential of three novel thieno[3,2-
b]pyridine derivatives 2e, 2f, 2h as anticancer agents in TNBC cell lines was demonstrated.
Importantly, no toxicity was observed in non-tumorigenic breast cells. One of the most
promising compounds, 2e, presented activity against TNBC both in vitro (by decreasing
viable cell number and cell proliferation and interfering with the cell cycle profile) and
in ovo (by reducing grafted tumor size). However, further studies must be carried out
to unravel the underlying mechanisms of action of this compound. Furthermore, the
anticancer effect of compound 2e should be also assessed in vivo, using xenografted mouse
models of human TNBC cell lines. Although the present work is focused on compound 2e,
the other promising compounds (2f and 2h) will be also explored in the future. Therefore,
this work highlights the antitumor potential of a novel thieno[3,2-b]pyridine derivative
against an aggressive type of cancer, TNBC.
Supplementary Materials: 1H, 13C and 19F NMR spectra of the novel compounds 2a–2h are pre-
sented.
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